Benzinga

Benzinga

Benzinga

venerdì, agosto 21

CytomX Therapeutics Inc

CTMXNASDAQ
Trade with Public
Trade with Public
$3.28
-0.01-0.3%
In chiusura: Aug 21, 5:00 PM EST
$3.28
N/A
Post-mercato: 4:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

CytomX Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CytomX Therapeutics (CTMX).

Price Target Range — 9 Quarters

Analyst Consensus — 10 Analysts

9Buy
1Hold
Consensus RatingOverweight# Analysts10Avg. Consensus PT$11Upside to Avg. PT+223.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026JP MorganAnupam RamaPT CutOverweight$12→$11
Aug 10, 2026GuggenheimMichael SchmidtPT CutBuy$15→$14
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $12.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $16.
Benzinga Newsdesk

PRO
Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $8 to $16.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved